Will Biosimilar Deal Change Orion Oyj's (HLSE:ORNBV) Narrative

• Orion Oyj reported two oncology updates: a European commercialisation deal with Qilu Pharma for an IV pembrolizumab biosimilar, and first patient dosing in the BICIDES Phase 1/2 ODM-216 trial.
• The combination of a partnered biosimilar revenue stream and Orion Oyj’s first biologic in human testing indicates a stronger operational focus on oncology-driven earnings over time.
• We will now see how Orion Oyj’s investment narrative could shift as investors weigh the Qilu pembrolizumab biosimilar commercialisation deal.

Spot oncology-focused momentum by scanning Orion Oyj alongside other cancer and immunotherapy plays in our hand picked list of 126 healthcare AI stocks.

Orion Oyj Investment Narrative Recap

To own Orion Oyj, you need to buy into a shift toward oncology driven earnings layered on top of an already profitable pharmaceuticals platform. The Qilu IV pembrolizumab biosimilar deal and ODM 216 first in human trial both point to that direction, but they do not immediately change the near term reliance on Nubeqa royalties and the broader portfolio.

The most important upcoming catalyst is the January to September 2026 interim report on 28 October, which will show how oncology and base business trends are tracking. The key risk is execution across multiple cancer programs and partnerships at once, where delays, weaker uptake or regulatory setbacks could weigh on growth expectations.

The Qilu IV pembrolizumab biosimilar agreement looks most relevant for Orion Oyj right now because it adds a concrete commercial angle to the oncology story. Orion gains exclusive European distribution, marketing and sales rights, while Qilu receives profit share plus development, regulatory and sales milestone payments, so economics will depend heavily on Orion’s ability to build volume.

For readers watching catalysts, this biosimilar could matter alongside existing drivers such as Nubeqa royalties and the oncology pipeline. The opportunity is an extra oncology revenue stream that does not require Orion to fund discovery, while the risk sits in pricing pressure, competition from other checkpoint inhibitors and the need to execute on launches across multiple European markets.

Orion Oyj's narrative points to forecast revenues of €2.6b and earnings of €747.9 million by 2029, based on analysts assuming 8.4% yearly revenue growth and an earnings increase of about €160.8 million from the €587.1 million reported today.

Uncover why Orion Oyj's fair value points to an 11% potential downside to its current price, a valuation premium that may not hold.

Exploring Other Perspectives

One alternate angle to watch is margin risk. The most optimistic analysts were already pencilling in revenue of €3.1b and earnings of €1.0b by 2029, with profit margins rising to 32.9%. That is far above consensus. The new Orion Oyj oncology updates could reinforce that optimism or push forecasts closer to the middle.

Explore 3 other Orion Oyj fair value estimates, including one that suggests there may be as much as 88% upside from the current price.

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Orion Oyj research is our analysis highlighting 3 key rewards that could impact your investment decision.
• See our latest analysis for Orion Oyj. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Orion Oyj's overall financial health at a glance.

Looking For More Ideas Beyond Orion Oyj?

If you want to stress test your view on Orion Oyj against a wider set of opportunities, casting a wider net with a structured stock search can help you compare quality, valuation and risk in a more disciplined way.

• For investors who care most about downside protection and steadier profiles, consider checking companies in our screener focused on 223 resilient stocks with low risk scores. This can be a way to balance an oncology heavy portfolio.
• If reliable balance sheets appeal to you more than headline stories, filter for businesses in the list of solid balance sheet and fundamentals (202 results) to find issuers that pair financial strength with fundamental support.
• When you want fresh ideas that the market might not be watching closely, use the screener highlighting 613 high quality undiscovered gems to surface less crowded opportunities that still show solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com